Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial-Reference-Cited by-同舟云学术

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial

Published:2015-03 Issue: Volume: Page:137
ISSN:1178-7007
Container-title:Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
language:en
Short-container-title:DMSO

Author:

Srivanichakorn Weerachai,Thongtang Nuntakorn,Sriwijitkamol Apiradee,Kongchoo Aroon,Sriussadaporn Sutin,Plengvidhya Nattachet,Lertwattanarak Raweewan,Vannasaeng Sathit

Publisher

Informa UK Limited

Subject

Pharmacology,Internal Medicine

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Initial eGlycemic Management System Dosing Strategy on Time to Target Blood Glucose Range;Journal of Diabetes Science and Technology;2021-02-15

2. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase‐4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials;Diabetes, Obesity and Metabolism;2020-01-27

Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea

;Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy;2019-05

4. The beta-cell death in long-term type 2 diabetes mellitus: never say never again;Minerva Endocrinologica;2018-12

5. The impact of non-medical switch on type 2 diabetes patients treated with canagliflozin in the commercially insured US population;Current Medical Research and Opinion;2018-05-03